Literature DB >> 1145932

Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment.

P C Sogani, B Ray, W F Whitmore.   

Abstract

Twenty-six patients with advanced prostatic carcinoma refractory to conventional endocrine treatment were treated with a new oral nonsteriodal antiandrogen, flutamide. There were 6 responders and 20 failures. No serious toxicity attributable to flutamide was observed.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1145932     DOI： 10.1016/0090-4295(75)90704-9

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


  6 in total

Review 1.  Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.

Authors:  R N Brogden; S P Clissold
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 2.  Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.

Authors:  F Labrie; A Dupont; A Bélanger; L Cusan; M Giguère; Y Lacourcière; I Luthy; D Bégin; C Labrie; J Simard
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment.

Authors:  M Schulz; A Schmoldt; F Donn; H Becker
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  The current status of scientific research and hormonal treatments for carcinoma of the prostate.

Authors:  J Waxman; A Saini
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

Review 5.  Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on.

Authors:  Eva Estébanez-Perpiñá; Charlotte L Bevan; Iain J McEwan
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

6.  Leuprorelin depot injection: patient considerations in the management of prostatic cancer.

Authors:  Zinelabidine Abouelfadel; E David Crawford
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.